论文部分内容阅读
目的:评价血清肿瘤标记物DR-70对恶性肿瘤的诊断价值。方法:用酶联免疫吸附双抗体夹心法测定20名正常人、15例良性疾病及42例恶性肿瘤患者的血清DR-70含量。结果:恶性肿瘤组与正常组、良性疾病组比较,血清DR-70均值显著升高(均为P<0.001),良性疾病组与正常组比较无显著差异(P>0.05)。血清DR-70检测恶性肿瘤的敏感性为83%,特异性为91%,准确性为87%。结论:血清DR-70是一个具有较高应用价值的广谱肿瘤标记物。
Objective: To evaluate the diagnostic value of serum tumor marker DR-70 in malignant tumors. Methods: Serum levels of DR-70 in 20 normal subjects, 15 benign diseases and 42 malignant tumors were determined by enzyme-linked immunosorbent assay (ELISA). Results: The average value of serum DR-70 in malignant tumor group was significantly higher than that in normal group and benign disease group (all P <0.001). There was no significant difference between benign disease group and normal group (P> 0.05). Serum DR-70 detection of malignancy was 83% sensitivity, specificity of 91%, accuracy of 87%. Conclusion: Serum DR-70 is a widely used tumor marker with high value.